Prudential Financial’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $29.6M | Buy |
225,051
+95,873
| +74% | +$12.7M | 0.04% | 313 |
|
|
2025
Q4 | $18.3M | Buy |
129,178
+26,330
| +26% | +$3.81M | 0.02% | 428 |
|
|
2025
Q3 | $14.4M | Sell |
102,848
-42,482
| -29% | -$5.76M | 0.02% | 531 |
|
|
2025
Q2 | $17.8M | Buy |
145,330
+26,030
| +22% | +$2.99M | 0.02% | 444 |
|
|
2025
Q1 | $13.5M | Sell |
119,300
-90,875
| -43% | -$11.5M | 0.02% | 483 |
|
|
2024
Q4 | $25.1M | Buy |
210,175
+33,450
| +19% | +$4.14M | 0.03% | 332 |
|
|
2024
Q3 | $20.4M | Sell |
176,725
-17,529
| -9% | -$2.4M | 0.03% | 449 |
|
|
2024
Q2 | $26.7M | Buy |
194,254
+78,136
| +67% | +$10.7M | 0.04% | 340 |
|
|
2024
Q1 | $16M | Sell |
116,118
-213,253
| -65% | -$29.1M | 0.02% | 508 |
|
|
2023
Q4 | $43.4M | Buy |
329,371
+50,204
| +18% | +$5.78M | 0.07% | 251 |
|
|
2023
Q3 | $31.5M | Buy |
279,167
+193,117
| +224% | +$20.3M | 0.05% | 328 |
|
|
2023
Q2 | $8.11M | Buy |
86,050
+21,980
| +34% | +$2.15M | 0.01% | 723 |
|
|
2023
Q1 | $6.4M | Buy |
64,070
+9,193
| +17% | +$957K | 0.01% | 796 |
|
|
2022
Q4 | $6.55M | Buy |
54,877
+5,227
| +11% | +$612K | 0.01% | 767 |
|
|
2022
Q3 | $5.15M | Buy |
49,650
+19,991
| +67% | +$2.03M | 0.01% | 876 |
|
|
2022
Q2 | $2.91M | Sell |
29,659
-31,192
| -51% | -$2.88M | ﹤0.01% | 1184 |
|
|
2022
Q1 | $5.71M | Buy |
60,851
+38,962
| +178% | +$3.3M | 0.01% | 919 |
|
|
2021
Q4 | $2.03M | Buy |
21,889
+4,096
| +23% | +$377K | ﹤0.01% | 1528 |
|
|
2021
Q3 | $1.72M | Sell |
17,793
-5,530
| -24% | -$522K | ﹤0.01% | 1538 |
|
|
2021
Q2 | $2.27M | Sell |
23,323
-15,208
| -39% | -$1.46M | ﹤0.01% | 1414 |
|
|
2021
Q1 | $3.75M | Sell |
38,531
-28,016
| -42% | -$2.94M | 0.01% | 1154 |
|
|
2020
Q4 | $6.38M | Sell |
66,547
-13,556
| -17% | -$1.31M | 0.01% | 909 |
|
|
2020
Q3 | $7.7M | Sell |
80,103
-11,527
| -13% | -$1.33M | 0.01% | 769 |
|
|
2020
Q2 | $11.2M | Buy |
91,630
+35,573
| +63% | +$3.93M | 0.02% | 660 |
|
|
2020
Q1 | $4.85M | Buy |
56,057
+10,613
| +23% | +$1.04M | 0.01% | 931 |
|
|
2019
Q4 | $4.88M | Buy |
45,444
+1,170
| +3% | +$123K | 0.01% | 1138 |
|
|
2019
Q3 | $3.99M | Buy |
44,274
+34,752
| +365% | +$3.25M | 0.01% | 1225 |
|
|
2019
Q2 | $804K | Sell |
9,522
-4,202
| -31% | -$345K | ﹤0.01% | 1948 |
|
|
2019
Q1 | $1.21M | Sell |
13,724
-12,749
| -48% | -$1.07M | ﹤0.01% | 1806 |
|
|
2018
Q4 | $1.89M | Buy |
26,473
+13
| +0% | +$1.25K | ﹤0.01% | 1538 |
|
|
2018
Q3 | $3.25M | Buy |
26,460
+21,890
| +479% | +$2.48M | ﹤0.01% | 1391 |
|
|
2018
Q2 | $449K | Hold |
4,570
| – | – | ﹤0.01% | 2078 |
|
|
2018
Q1 | $379K | Hold |
4,570
| – | – | ﹤0.01% | 2082 |
|
|
2017
Q4 | $355K | Sell |
4,570
-700
| -13% | -$47.7K | ﹤0.01% | 2102 |
|
|
2017
Q3 | $323K | Hold |
5,270
| – | – | ﹤0.01% | 2123 |
|
|
2017
Q2 | $242K | Sell |
5,270
-172,200
| -97% | -$8.35M | ﹤0.01% | 2212 |
|
|
2017
Q1 | $7.68M | Sell |
177,470
-62,700
| -26% | -$2.69M | 0.01% | 955 |
|
|
2016
Q4 | $9.29M | Buy |
240,170
+8,357
| +4% | +$378K | 0.01% | 882 |
|
|
2016
Q3 | $11.7M | Sell |
231,813
-32,850
| -12% | -$1.64M | 0.02% | 771 |
|
|
2016
Q2 | $12M | Sell |
264,663
-522
| -0.2% | -$24K | 0.02% | 751 |
|
|
2016
Q1 | $10.5M | Buy |
265,185
+177,088
| +201% | +$7.03M | 0.02% | 791 |
|
|
2015
Q4 | $4.98M | Hold |
88,097
| – | – | 0.01% | 1074 |
|
|
2015
Q3 | $3.5M | Buy |
88,097
+170
| +0.2% | +$8.22K | 0.01% | 1192 |
|
|
2015
Q2 | $4.2M | Hold |
87,927
| – | – | 0.01% | 1191 |
|
|
2015
Q1 | $3.49M | Buy |
87,927
+200
| +0.2% | +$7.15K | 0.01% | 1315 |
|
|
2014
Q4 | $1.96M | Sell |
87,727
-900
| -1% | -$17.1K | ﹤0.01% | 1476 |
|
|
2014
Q3 | $1.39M | Sell |
88,627
-8,477
| -9% | -$127K | ﹤0.01% | 1600 |
|
|
2014
Q2 | $1.44M | Buy |
97,104
+8,377
| +9% | +$118K | ﹤0.01% | 1673 |
|
|
2014
Q1 | $1.43M | Buy |
88,727
+400
| +0.5% | +$6.84K | ﹤0.01% | 1630 |
|
|
2013
Q4 | $825K | Sell |
88,327
-300
| -0.3% | -$2.93K | ﹤0.01% | 1821 |
|
|
2013
Q3 | $1M | Sell |
88,627
-38,600
| -30% | -$531K | ﹤0.01% | 1735 |
|
|
2013
Q2 | $1.7M | Buy |
+127,227
| New | +$1.56M | ﹤0.01% | 1466 |
|
Other funds holding NBIX
VPM
VCM
Prudential Financial's NBIX Position: Q1 2026 in Review
Prudential Financial increased its Neurocrine Biosciences (NBIX) stake by 74% in Q1 2026, buying an estimated $12.7M and bringing the position to 225,051 shares worth $29.6M. The position accounts for 0.04% of the portfolio, ranked #313.
Prudential Financial first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $43.4M in Q4 2023. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Prudential Financial held 225,051 shares of Neurocrine Biosciences worth $29.6M as of Q1 2026.
- Prudential Financial bought 95,873 Neurocrine Biosciences shares in Q1 2026, an estimated $12.7M.
- Neurocrine Biosciences made up 0.04% of Prudential Financial's portfolio in Q1 2026, its #313 holding.
- Prudential Financial first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
- Prudential Financial's Neurocrine Biosciences position peaked at $43.4M in Q4 2023.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.